Brief: Rad Receives Approval For Phase 1 Therapeutic Study Of Pdl1-Nanobody In Non-Small Cell Lung Cancer
09/10/2023 13:30
Oct 9 (Reuters) - Radiopharm Theranostics Ltd RAD.AX :
* RAD RECEIVES APPROVAL FOR PHASE 1 THERAPEUTIC STUDY OF
PDL1-NANOBODY IN NON-SMALL CELL LUNG CANCER
* RADIOPHARM THERANOSTICS LTD - TRIAL IS EXPECTED TO START
SHORTLY
Source text for Eikon: ID:nGNX8Hpqry
Further company coverage: RAD.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Radiopharm Theranostics
See all newsBrief: Radiopharm Theranostics Advances To Cohort 3 In 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial
Brief: Radiopharm Theranostics And Siemens Healthineers Sign Clinical Supply Agreement For Rad101 In The U.S.
Brief: Radiopharm Theranostics Says RAD And Siemens Sign Clinical Supply Agreement For Rad101
Brief: Radiopharm Theranostics Doses First Patient In Phase 1/2A Clinical Study Of Betabart
Brief: Radiopharm Theranostics Says Co Increases Ownership In Radiopharm Ventures To 87.5%